<?xml version="1.0" encoding="UTF-8"?>
<p>
 <xref ref-type="fig" rid="pntd.0006469.g002">Fig 2</xref> shows that IDCs invest above the average on NTDs in a critical component, or determinant, of health innovation: research and development [
 <xref rid="pntd.0006469.ref002" ref-type="bibr">2</xref>, 
 <xref rid="pntd.0006469.ref022" ref-type="bibr">22</xref>, 
 <xref rid="pntd.0006469.ref023" ref-type="bibr">23</xref>]: Seven of the nine countries prioritizing NTDs R&amp;D, are IDCs: Brazil, Thailand, Argentina, Indonesia, India, Mexico and Malaysia. The two industrialized countries that this study demonstrated that are also part of this top group, Singapore and Switzerland, have built and run two institutions fully dedicated to R&amp;D on NTDs: the Novartis Institute for Tropical Diseases (NITD) in Singapore and the Swiss Tropical and Public Health Institute (Swiss TPH) in Basel.
</p>
